Drug Profile

Research programme: targeted high-affinity natural killer cell therapy - ImmunityBio

Alternative Names: CD123.t-haNK; CD33.t-haNK; CSPG4.t-haNK; EGFR.t-haNK; FLT3.t-haNK; Her2.t-haNK

Latest Information Update: 28 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NantKwest
Developer ImmunityBio
Class CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jan 2023 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Parenteral)
09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
02 Apr 2019 NantKwest has patent protection for haNK natural killer cell technology platform in Europe

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com